KRONİK MİYELOSİTER LÖSEMİ Prof. Dr. Osman İlhan A.Ü.T.F. İbni ...

18- Ilhan O, Ozcan M, Yalçın A, et al. Interferon alpha2a and low dose cytarabine in
chronic myeloid leukemia: second interim analysis of multicenter study. Blood 1998,
92 (Suppl 2) 246: 4056a
19- Beelen DW, Graeven U, Elmaagaclı AH, et al. Prolonged administration of interferonalpha
in patients with chronic phase Philedelphia chromosome positive chronic
myelogeneous leukemia before Allogeneic bone marrow transplantation may
adversely affect transplant outcome. Blood 1995, 85: 2981-2990
20- Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interferonalpha
and outcome after unrelated donor marrow transplantation of chronic
myelogenous leukemia in chronic phase. Blood 1998, 92: 394-401
21- Beksac M, Celebi H, Sargın D, et al. Role of pretransplant interferon-alpha (IFN)
treatment in the outcome of stem cell transplantation (SCT) from related donors in
chronic myelogeneous leukemia (CML): results from three Turkish transplant centers.
22- Capdeville R and Silberman S. Imatinib: a targeted clinical drug development. Semin
Hematol 2003, 40: 15-20
23- Druker BJ, Tamura S, Buncdunger E, et al. Effects of selective inhibitor of Abl
tyrosine kinase on growth of BCR-ABL positive cells Nat Med 1996, 2: 561-566
24- Druker BJ, Talpaz M, Resta D, et al Efficacy and safety spesific inhibitor of the Bcr-
Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344: 1031-1037
25- Druker BJ, Sawyer JL, Kantarjian H, et al. Activity of the specific inhibitor of the Bcr-
Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute
lymphoblastic leukemia with the Philedelphia chromosome. N Engl J Med, 2001 344:
1038-1042
26- Druker BJ. Imatinib Alone and in Combination for Chronic Myeloid Leukemia.
Seminar Hematol 2003, 40: 50-58
27- Kantarjian H, Sawyer J, Hochhaus A, et al. hematologic and cytogenetic responses to
imatinib mesylate in chronic myelogeneous leukemia. N Engl J Med 2002, 346: 645-
652
28- Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and
cytogenetic responses in patients with accelerated phase chronic myeloid leukemia:
Results of a phase 2 study. Blood 2003, 1928-1937
29- Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and
cytogentic responses in patients with chronic myeloid leukemia in myeloid blast crisis:
Results of phase II study. Blood 2002, 99: 3530-3539
30- Druker BJ, for the IRIS (International Randomized IFN vs STI571) Study Group:
STI571 (Gleevec/Glivec, Imatinib) versus interferon (IFN) + Cytarabine as initial
therapy for patients with CML: Results of a randomized study. Proc Am Soc Clin Onc
21: 1a, 2002 (abstr)
31- Goldman JM. Chronic myeloid leukemia-still a few questions. Exp Hematol 2004, 32:
2-10
32- Kantarjian H, Talpaz M, O’Brien S, et al. High-dose Imatinib mesylate therapy in
newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid
leukemia. Blood 2003, Dec (First Edition, prepublished online)
33- Grathwohl A. Prognostic factors in chronic myeloid leukemia allografting. Seminar
Hematol 2003, 40:13-21
34- Van Rhee F, Szydlo RM, Hermans J ve ark. Leukemia WP of EBMT: Long term
results after allogeneic bone marrow transplantation for CML in chronic phase. Bone
Marrow Transplant 1997, 20:553